FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220995145> ?p ?o ?g. }

• W4220995145 endingPage "1832" @default.
• W4220995145 startingPage "1826" @default.
• W4220995145 abstract "There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are exposed to ustekinumab or vedolizumab. We assessed the risk of subsequent cancer in patients exposed to these agents.We performed a retrospective cohort study of patients with IBD and a history of cancer at an academic medical center between January 2013 and December 2020. We collected data on demographics, IBD and cancer disease characteristics, and drug exposures. The primary exposure was immunosuppressive therapy after diagnosis of cancer. The primary outcome was interval development of new or recurrent cancer.Of 390 patients with IBD and a previous history of cancer, 37 were exposed to vedolizumab, 14 ustekinumab, 41 antitumor necrosis factor (anti-TNF), and 31 immunomodulator; and 267 were not exposed to immunosuppression following cancer diagnosis. During a total median follow-up time of 52 months, 81 (20%) patients developed subsequent cancer: 6 (16%) were exposed to vedolizumab, 2 (14%) to ustekinumab, 3 (10%) to immunomodulators, 12 (29%) to anti-TNF, and 56 (21%) with no immunosuppression (P = .41). In a multivariable Cox model adjusting for age, IBD subtype, smoking, cancer recurrence risk, and cancer stage, there was no increase in subsequent cancer with vedolizumab (adjusted hazard ratio, 1.36; 95% CI, 0.27-7.01) or ustekinumab (adjusted hazard ratio, 0.96; 95% CI, 0.17-5.41). Patients with more than 1 biologic exposure also did not have an increased risk of subsequent cancer.Exposure to ustekinumab or vedolizumab in patients with IBD and a prior history of cancer does not appear to be associated with an increased risk of subsequent new or recurrent cancer." @default.
• W4220995145 created "2022-04-03" @default.
• W4220995145 creator A5012629328 @default.
• W4220995145 creator A5016785345 @default.
• W4220995145 creator A5023694681 @default.
• W4220995145 creator A5035941245 @default.
• W4220995145 creator A5037576846 @default.
• W4220995145 creator A5039145221 @default.
• W4220995145 creator A5072158096 @default.
• W4220995145 creator A5081605770 @default.
• W4220995145 date "2022-03-09" @default.
• W4220995145 modified "2023-10-01" @default.
• W4220995145 title "Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy" @default.
• W4220995145 cites W1410441244 @default.
• W4220995145 cites W1970754981 @default.
• W4220995145 cites W1995372822 @default.
• W4220995145 cites W1996491123 @default.
• W4220995145 cites W2002780176 @default.
• W4220995145 cites W2004499699 @default.
• W4220995145 cites W2024763754 @default.
• W4220995145 cites W2077531651 @default.
• W4220995145 cites W2080450248 @default.
• W4220995145 cites W2112604373 @default.
• W4220995145 cites W2142612410 @default.
• W4220995145 cites W2142796823 @default.
• W4220995145 cites W2148298419 @default.
• W4220995145 cites W2162805528 @default.
• W4220995145 cites W2291705929 @default.
• W4220995145 cites W2301614008 @default.
• W4220995145 cites W2316668818 @default.
• W4220995145 cites W2395443616 @default.
• W4220995145 cites W2413203763 @default.
• W4220995145 cites W2768739636 @default.
• W4220995145 cites W2910072039 @default.
• W4220995145 cites W2919081348 @default.
• W4220995145 cites W2948759662 @default.
• W4220995145 cites W2999237458 @default.
• W4220995145 cites W3017396921 @default.
• W4220995145 cites W3093402879 @default.
• W4220995145 cites W3164828618 @default.
• W4220995145 cites W4205253993 @default.
• W4220995145 cites W4233817719 @default.
• W4220995145 doi "https://doi.org/10.1093/ibd/izac035" @default.
• W4220995145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35262671" @default.
• W4220995145 hasPublicationYear "2022" @default.
• W4220995145 type Work @default.
• W4220995145 citedByCount "18" @default.
• W4220995145 countsByYear W42209951452022 @default.
• W4220995145 countsByYear W42209951452023 @default.
• W4220995145 crossrefType "journal-article" @default.
• W4220995145 hasAuthorship W4220995145A5012629328 @default.
• W4220995145 hasAuthorship W4220995145A5016785345 @default.
• W4220995145 hasAuthorship W4220995145A5023694681 @default.
• W4220995145 hasAuthorship W4220995145A5035941245 @default.
• W4220995145 hasAuthorship W4220995145A5037576846 @default.
• W4220995145 hasAuthorship W4220995145A5039145221 @default.
• W4220995145 hasAuthorship W4220995145A5072158096 @default.
• W4220995145 hasAuthorship W4220995145A5081605770 @default.
• W4220995145 hasBestOaLocation W42209951452 @default.
• W4220995145 hasConcept C121608353 @default.
• W4220995145 hasConcept C126322002 @default.
• W4220995145 hasConcept C143998085 @default.
• W4220995145 hasConcept C207103383 @default.
• W4220995145 hasConcept C2776207728 @default.
• W4220995145 hasConcept C2777138892 @default.
• W4220995145 hasConcept C2778260677 @default.
• W4220995145 hasConcept C2778975655 @default.
• W4220995145 hasConcept C2779134260 @default.
• W4220995145 hasConcept C2779280984 @default.
• W4220995145 hasConcept C44249647 @default.
• W4220995145 hasConcept C71924100 @default.
• W4220995145 hasConceptScore W4220995145C121608353 @default.
• W4220995145 hasConceptScore W4220995145C126322002 @default.
• W4220995145 hasConceptScore W4220995145C143998085 @default.
• W4220995145 hasConceptScore W4220995145C207103383 @default.
• W4220995145 hasConceptScore W4220995145C2776207728 @default.
• W4220995145 hasConceptScore W4220995145C2777138892 @default.
• W4220995145 hasConceptScore W4220995145C2778260677 @default.
• W4220995145 hasConceptScore W4220995145C2778975655 @default.
• W4220995145 hasConceptScore W4220995145C2779134260 @default.
• W4220995145 hasConceptScore W4220995145C2779280984 @default.
• W4220995145 hasConceptScore W4220995145C44249647 @default.
• W4220995145 hasConceptScore W4220995145C71924100 @default.
• W4220995145 hasFunder F4320312926 @default.
• W4220995145 hasFunder F4320332161 @default.
• W4220995145 hasFunder F4320337357 @default.
• W4220995145 hasIssue "12" @default.
• W4220995145 hasLocation W42209951451 @default.
• W4220995145 hasLocation W42209951452 @default.
• W4220995145 hasLocation W42209951453 @default.
• W4220995145 hasOpenAccess W4220995145 @default.
• W4220995145 hasPrimaryLocation W42209951451 @default.
• W4220995145 hasRelatedWork W2317479536 @default.
• W4220995145 hasRelatedWork W2586347006 @default.
• W4220995145 hasRelatedWork W2767911405 @default.
• W4220995145 hasRelatedWork W3021087471 @default.
• W4220995145 hasRelatedWork W3048212227 @default.
• W4220995145 hasRelatedWork W3092454324 @default.

• next